GAMMA Investing LLC Has $50,000 Stock Position in STAAR Surgical (NASDAQ:STAA)

GAMMA Investing LLC boosted its holdings in STAAR Surgical (NASDAQ:STAA) by 313.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 1,308 shares of the medical instruments supplier’s stock after acquiring an additional 992 shares during the quarter. GAMMA Investing LLC’s holdings in STAAR Surgical were worth $50,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of STAA. Cape Investment Advisory Inc. acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $42,000. Quest Partners LLC bought a new stake in shares of STAAR Surgical during the fourth quarter worth $146,000. PNC Financial Services Group Inc. increased its holdings in shares of STAAR Surgical by 171.5% during the third quarter. PNC Financial Services Group Inc. now owns 3,755 shares of the medical instruments supplier’s stock worth $151,000 after buying an additional 2,372 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in shares of STAAR Surgical by 10.7% in the 4th quarter. Perigon Wealth Management LLC now owns 7,288 shares of the medical instruments supplier’s stock valued at $227,000 after acquiring an additional 703 shares during the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in shares of STAAR Surgical during the 4th quarter valued at $323,000. Institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

STAA has been the subject of a number of recent research reports. Piper Sandler upped their target price on STAAR Surgical from $33.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, May 8th. Stifel Nicolaus reissued a “buy” rating and set a $50.00 target price on shares of STAAR Surgical in a report on Monday, April 1st. William Blair raised shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 4th. Finally, Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $46.00 to $43.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $47.00.

STAAR Surgical Stock Up 1.0 %

STAA stock opened at $41.15 on Tuesday. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 132.74 and a beta of 0.65. The company’s fifty day simple moving average is $42.97 and its 200 day simple moving average is $37.28. STAAR Surgical has a 12-month low of $26.66 and a 12-month high of $58.82.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). STAAR Surgical had a return on equity of 6.83% and a net margin of 4.69%. The business had revenue of $77.40 million during the quarter, compared to the consensus estimate of $75.34 million. During the same period last year, the business posted $0.05 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. Research analysts expect that STAAR Surgical will post 0.08 earnings per share for the current year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.